Abstract | PURPOSE: PATIENTS AND METHODS: Thirty patients with advanced pancreatic cancer were immunized with three doses of either 100 micro g or 250 micro g of G17DT. RESULTS: In the whole group, 20 (67%) of 30 patients produced an antibody response. The 250- micro g dose resulted in a significantly greater response rate of 82% compared with 46% for the 100- micro g group (P =.018). The most significant side effects, seen in three patients, were local abscess and/or fever. The median survival for the whole group from the date of the first immunization was 187 days; median survival was 217 days for the antibody responders and 121 days for the antibody nonresponders. The difference in survival between the antibody responders and nonresponders was significant (P =.0023). CONCLUSION: Patients with advanced pancreatic cancer are able to mount an adequate antibody response to G17DT. The 250- micro g dose is superior to the 100- micro g dose, and it appears to be generally well tolerated. Antibody responders demonstrate significantly greater survival than antibody nonresponders. Phase III studies are currently underway in order to determine efficacy.
|
Authors | B T Brett, S C Smith, C V Bouvier, D Michaeli, D Hochhauser, B R Davidson, T R Kurzawinski, A F Watkinson, N Van Someren, R E Pounder, M E Caplin |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 20
Issue 20
Pg. 4225-31
(Oct 15 2002)
ISSN: 0732-183X [Print] United States |
PMID | 12377966
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Cancer Vaccines
- Diphtheria Toxoid
- Gastrins
- gastrin immunogen
|
Topics |
- Adult
- Aged
- Antibody Formation
- Antineoplastic Agents
(immunology, therapeutic use)
- Cancer Vaccines
- Diphtheria Toxoid
(immunology, therapeutic use)
- Female
- Gastrins
(immunology, therapeutic use)
- Humans
- Immunization
- Male
- Middle Aged
- Pancreatic Neoplasms
(drug therapy, immunology, metabolism)
- Quality of Life
- Survival Analysis
|